(n-phosphonacetyl-l-aspartato)...

Details (n-phosphonacetyl-l-aspartato)... (n-phosphonacetyl-l-aspartato)...

C - Chemistry, Metallurgy

07

F

260/429.4

C07F 15/00 (2006.01) C07F 9/38 (2006.01)

Patent

CA 1151663

ABSTRACT OF THE DISCLOSURE Image where X is Na+, K+, Li+, NH4 or H (N-phosphonacetyl-L-aspartato) (1,2-diaminocyclohexane)platinum(II) or alkali metal or ammonium salt thereof has shown antitumor activity in animals such as activity against murine leukemia L1210. Additionally, this agent is used against B-16 and Colon 38 tumors and also Ehrlich ascites tumor. It is effective in dosages of 5-60 mg/kg of body weight and is potentiated in a treatment with cyclophosphamide (CY) (50 mg/kg of body weight) to which may be added hydroxyurea (HU) (1000-1500 mg/kg of body weight). In binary treat- ment with cis-dichlorodiamineplatinum(II) (or cisplatin) the preferred ratio of the present compound to cisplatin is about 10:1 with a range of about 10:1 to 1:10 in mg/kg of body weight. The present platinum compound may be pre- pared by reacting the known L-aspartic acid, N-(phosphonacetyl-)disodium salt (PALA; NSC-224131), with dinitrato(1,2-diaminocyclohexane)platinum(II) (NSC- 239851). This compound N-phosphonacetyl-L-aspartato (1,2-diaminocyclohexane) platinum (II) may be combined in multiple drug regimen with substantially improved yield cures over the parent compounds. For example, the compound denoted Pt-268 may be combined in a dual regimen with cyclophosphamide (CY), hydroxyurea (HU), and cisplatin.

356429

Affiliated with

Also associated with

Rating

(n-phosphonacetyl-l-aspartato)... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with (n-phosphonacetyl-l-aspartato)..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and (n-phosphonacetyl-l-aspartato)... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFCA-PAI-O-478529